Found 29 results
Author Title [ Type
Filters: Author is VanVeldhuisen, Paul C [Clear All Filters]
“The Advanced Glaucoma Intervention Study (Agis): 13. Comparison Of Treatment Outcomes Within Race: 10-Year Results.”. Ophthalmology 111 (4). Ophthalmology: 651-64. doi:10.1016/j.ophtha.2003.09.025.
. 2004. “The Advanced Glaucoma Intervention Study (Agis): 14. Distinguishing Progression Of Glaucoma From Visual Field Fluctuations.”. Ophthalmology 111 (11). Ophthalmology: 2109-16. doi:10.1016/j.ophtha.2004.06.029.
. 2004. “Baseline Factors Associated With 6-Month Visual Acuity And Retinal Thickness Outcomes In Patients With Macular Edema Secondary To Central Retinal Vein Occlusion Or Hemiretinal Vein Occlusion: Score2 Study Report 4.”. Jama Ophthalmol 135 (6). Jama Ophthalmol: 639-649. doi:10.1001/jamaophthalmol.2017.1141.
. 2017. “Baseline Predictors Of Visual Acuity And Retinal Thickness Outcomes In Patients With Retinal Vein Occlusion: Standard Care Versus Corticosteroid For Retinal Vein Occlusion Study Report 10.”. Ophthalmology 118 (2). Ophthalmology: 345-52. doi:10.1016/j.ophtha.2010.06.034.
. 2011. “Characteristics Associated With Severe Perineal And Cervical Lacerations During Vaginal Delivery.”. Obstet Gynecol 117 (3). Obstet Gynecol: 627-35. doi:10.1097/AOG.0b013e31820afaf2.
. 2011. “Comparison Of Monthly Vs Treat-And-Extend Regimens For Individuals With Macular Edema Who Respond Well To Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From The Score2 Randomized Clinical Trial.”. Jama Ophthalmol 136 (4). Jama Ophthalmol: 337-345. doi:10.1001/jamaophthalmol.2017.6843.
. 2018. “Effect Of Bevacizumab Vs Aflibercept On Visual Acuity Among Patients With Macular Edema Due To Central Retinal Vein Occlusion: The Score2 Randomized Clinical Trial.”. Jama 317 (20). Jama: 2072-2087. doi:10.1001/jama.2017.4568.
. 2017. “Effect Of Oral Valproic Acid Vs Placebo For Vision Loss In Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.”. Jama Ophthalmol 136 (8). Jama Ophthalmol: 849-856. doi:10.1001/jamaophthalmol.2018.1171.
. 2018. “Hair Analysis And Its Concordance With Self-Report For Drug Users Presenting In Emergency Department.”. Drug Alcohol Depend 167. Drug Alcohol Depend: 149-55. doi:10.1016/j.drugalcdep.2016.08.007.
. 2016. “Incidence, Risk Factors, And Timing Of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection For Macular Edema Secondary To Retinal Vein Occlusion: Score Study Report 15.”. Jama Ophthalmol 133 (9). Jama Ophthalmol: 1022-9. doi:10.1001/jamaophthalmol.2015.1823.
. 2015. “Long-Term Physical Stability, Sterility, And Anti-Vegf Bioactivity Of Repackaged Bevacizumab In 2-Ml Glass Vials.”. Retina 39 (9). Retina: 1802-1809. doi:10.1097/IAE.0000000000002212.
. 2019. “Month 12 Outcomes After Treatment Change At Month 6 Among Poor Responders To Aflibercept Or Bevacizumab In Eyes With Macular Edema Secondary To Central Or Hemiretinal Vein Occlusion: A Secondary Analysis Of The Score2 Study.”. Jama Ophthalmol 137 (3). Jama Ophthalmol: 281-287. doi:10.1001/jamaophthalmol.2018.6111.
. 2019. “Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy For Macular Edema Due To Central Retinal Or Hemiretinal Vein Occlusion: Score2 Report 10: A Secondary Analysis Of The Score2 Randomized Clinical Trial.”. Jama Ophthalmol. Jama Ophthalmol. doi:10.1001/jamaophthalmol.2019.3947.
. 2019. “Natural History Of Viral Markers In Children Infected With Human T Lymphotropic Virus Type I In Jamaica.”. J Infect Dis 194 (5). J Infect Dis: 552-60. doi:10.1086/506365.
. 2006. “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy For Macular Edema Due To Central Retinal Or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis Of A Randomized Clinical Trial.”. Jama Ophthalmol. Jama Ophthalmol. doi:10.1001/jamaophthalmol.2019.1519.
. 2019. “Power Of Automated Algorithms For Combining Time-Line Follow-Back And Urine Drug Screening Test Results In Stimulant-Abuse Clinical Trials.”. Am J Drug Alcohol Abuse 37 (5). Am J Drug Alcohol Abuse: 350-7. doi:10.3109/00952990.2011.601777.
. 2011. “Prescription Opioid Registry Protocol In An Integrated Health System.”. Am J Manag Care 23 (5). Am J Manag Care: e146-e155.
. 2017. “A Randomized Trial Comparing The Efficacy And Safety Of Intravitreal Triamcinolone With Observation To Treat Vision Loss Associated With Macular Edema Secondary To Central Retinal Vein Occlusion: The Standard Care Vs Corticosteroid For Retinal Vein Occlus”. Arch Ophthalmol 127 (9). Arch Ophthalmol: 1101-14. doi:10.1001/archophthalmol.2009.234.
. 2009. “Score Study Report 1: Baseline Associations Between Central Retinal Thickness And Visual Acuity In Patients With Retinal Vein Occlusion.”. Ophthalmology 116 (3). Ophthalmology: 504-12. doi:10.1016/j.ophtha.2008.10.017.
. 2009. “Score Study Report #11: Incidences Of Neovascular Events In Eyes With Retinal Vein Occlusion.”. Ophthalmology 118 (7). Ophthalmology: 1364-72. doi:10.1016/j.ophtha.2010.11.020.
. 2011. “Score Study Report 12: Development Of Venous Collaterals In The Score Study.”. Retina 33 (2). Retina: 287-95. doi:10.1097/IAE.0b013e318263d106.
. 2013. “Score Study Report 2: Interobserver Agreement Between Investigator And Reading Center Classification Of Retinal Vein Occlusion Type.”. Ophthalmology 116 (4). Ophthalmology: 756-61. doi:10.1016/j.ophtha.2008.11.015.
. 2009. “Score Study Report 3: Study Design And Baseline Characteristics.”. Ophthalmology 116 (9). Ophthalmology: 1770-1777.e1. doi:10.1016/j.ophtha.2009.03.022.
. 2009. “Score Study Report 7: Incidence Of Intravitreal Silicone Oil Droplets Associated With Staked-On Vs Luer Cone Syringe Design.”. Am J Ophthalmol 148 (5). Am J Ophthalmol: 725-732.e7. doi:10.1016/j.ajo.2009.06.004.
. 2009. “Score Study Report 8: Closed Tests For All Pair-Wise Comparisons Of Means.”. Drug Inf J 44 (4). Drug Inf J: 405-420. doi:10.1177/009286151004400405.
. 2010.